Evidence map›Paper›PMID 28025618›Full record

ArticleJournal of materials chemistry. B2017

AB3-Loaded and Tumor-Targeted Unimolecular Micelles for Medullary Thyroid Cancer Treatment.

Renata Jaskula-Sztul, Guojun Chen, Ajitha Dammalapati, April Harrison, Weiping Tang, Shaoqin Gong, Herbert Chen

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of materials chemistry. B, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
2.7field-weighted citation impact, top 11% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 23 citations in OpenAlex.

  1. Review
  2. Chemical Approaches to Synthetic Drug Delivery Systems for Systemic Applications.Angewandte Chemie (International ed. in English) · 2022
    Review
  3. Review
  4. Article
  5. Article
  6. Review
  7. Review
  8. Review
  9. Article
  10. Tumor-targeted pH/redox dual-sensitive unimolecular nanoparticles for efficient siRNA delivery.Journal of controlled release : official journal of the Controlled Release Society · 2017
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 4 institutions in 1 country.

Renata Jaskula-SztulDepartment of Surgery, School of Medicine University of Alabama at Birmingham, Birmingham, AL 35233, USA.
Guojun ChenDepartment of Materials Science and Engineering, University of Wisconsin-Madison, Madison, WI 53715, USA; Wisconsin Institute for Discovery, University of Wisconsin-Madison, Madison, WI 53715, USA.
Ajitha DammalapatiDepartment of Surgery, School of Medicine and Public Health, University of Wisconsin-Madison, Madison, WI 53706, USA.
April HarrisonDepartment of Surgery, School of Medicine and Public Health, University of Wisconsin-Madison, Madison, WI 53706, USA.
Weiping TangSchool of Pharmacy, University of Wisconsin-Madison, Madison, WI 53706, USA.
Shaoqin GongDepartment of Materials Science and Engineering, University of Wisconsin-Madison, Madison, WI 53715, USA; Wisconsin Institute for Discovery, University of Wisconsin-Madison, Madison, WI 53715, USA; Department of Biomedical Engineering, University of Wisconsin-Madison, Madison, WI 53706, USA.
Herbert ChenDepartment of Surgery, School of Medicine University of Alabama at Birmingham, Birmingham, AL 35233, USA.
Madison Group (United States) · USUniversity of Alabama at Birmingham · USUniversity of Wisconsin–Madison · USWisconsin Institutes for Discovery · US

Funding

GSK3-beta Signaling in Medullary Thyroid CancerR01CA121115 · NCI · UNIVERSITY OF WISCONSIN-MADISON · PI CHEN, HERBERT · 2009 to 2013
$1.5M
Targeted Therapy of Neuroendocrine Cancers Via the Notch Signaling PathwayK25CA166178 · NCI · UNIVERSITY OF WISCONSIN-MADISON · PI GONG, SHAOQIN - · 2013 to 2017
$994k
Targeting Triple Negative Breast Cancer Using Nanoparticles Loaded with the Anti-Cancer Drug AminoflavoneR21CA196653 · NCI · UNIVERSITY OF WISCONSIN-MADISON · PI GONG, SHAOQIN -, XU, WEI · 2016 to 2017
$337k
NCI NIH HHS K25 CA166178NCI NIH HHS R01 CA121115NCI NIH HHS R21 CA196653
6 · The paper itself

Abstract

Medullary thyroid cancer (MTC) is often resistant to standard therapies, emphasizing the need for the development of other treatments. A new histone deacetylase inhibitor, AB3, can effectively inhibit MTC cell proliferation

Indexed as

HDAC inhibitorKE108Medullary thyroid cancersomatostatin receptortargeted drug deliveryunimolecular micelles

Identifiers

PMID28025618
PMCPMC5180596
OpenAlexW2559657414

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.